<p>Advisory Services Network LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中披露，其在輝瑞公司（NYSE:PFE - 免費報告）的持股在第四季度增加了 3.5%。該基金在季度內購買了額外的 11,502 股後，持有該生物製藥公司 339,805 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Advisory Services Network LLC 在輝瑞的持股價值為 9,015,000 美元。</p>
<ul>
<li>關注這兩隻醫療保健股票，因為摩根大通提升了吉利德的評級</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也調整了對 PFE 的持股。Nordea Investment Management AB 在第四季度將其在輝瑞的股份增加了 36.1%。Nordea Investment Management AB 目前持有 4,071,700 股該生物製藥公司的股票，價值 108,002,000 美元，此前在該期間內又收購了 1,080,822 股。Parsons Capital Management Inc. RI 在第四季度將其在輝瑞的持股增加了 118.7%。Parsons Capital Management Inc. RI 目前持有 294,764 股該生物製藥公司的股票，價值 7,820,000 美元，此前在上個季度又購買了 159,984 股。Copley Financial Group Inc. 在第三季度購買了輝瑞的新頭寸，價值約 577,000 美元。Geode Capital Management LLC 在第三季度將其在輝瑞的持股增加了 1.6%。Geode Capital Management LLC 目前持有 117,666,245 股該生物製藥公司的股票，價值 3,392,342,000 美元，此前在該期間內又購買了 1,855,419 股。最後，Mcdonald Partners LLC 在第四季度將其在輝瑞的持股增加了 9.9%。Mcdonald Partners LLC 目前持有 110,296 股該生物製藥公司的股票，價值 2,926,000 美元，此前在該期間內又購買了 9,963 股。68.36% 的股票由機構投資者持有。</p>
<h2>輝瑞價格表現</h2>
<p>輝瑞股票週三開盤價為 21.75 美元。該公司的市值為 1233.3 億美元，市盈率為 15.42，PEG 比率為 0.64，貝塔值為 0.67。該公司的速動比率為 0.73，流動比率為 1.00，債務股本比率為 0.63。該股票的 50 日簡單移動平均線為 25.59 美元，200 日簡單移動平均線為 26.58 美元。輝瑞公司的 52 周低點為 21.19 美元，52 周高點為 31.54 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 2 月 4 日星期二發佈了季度財報。這家生物製藥公司報告該季度每股收益為 0.63 美元，超出分析師一致預期的 0.48 美元，超出幅度為 0.15 美元。輝瑞的股本回報率為 19.47%，淨利潤率為 12.62%。該公司該季度的收入為 177.6 億美元，而分析師預期為 172.6 億美元。在去年同期，該公司每股收益為 0.10 美元。與去年同期相比，該公司的收入增長了 24.7%。整體來看，分析師預計輝瑞公司在當前財政年度的每股收益將達到 2.95。</p>
<h2>分析師升級和降級</h2>
<p>一些股票分析師最近對 PFE 股票發佈了報告。Truist Financial 將輝瑞的目標價從 36.00 美元下調至 32.00 美元，並在 12 月 18 日的研究報告中對該股票給予了 “買入” 評級。Guggenheim 在 3 月 18 日的研究報告中重申了對輝瑞股票的 “買入” 評級。美國銀行在 12 月 10 日的研究報告中重申了 “中性” 評級，並將輝瑞股票的目標價設定為 29.00 美元。高盛集團在週二的研究報告中重申了 “中性” 評級，並將輝瑞股票的目標價設定為 25.00 美元（從 32.00 美元下調）。最後，滙豐全球研究在 3 月 10 日的研究報告中將輝瑞股票的評級提升至 “強力買入”。一位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，六位分析師給予了買入評級，三位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，輝瑞目前的平均評級為 “適度買入”，共識目標價為 31.07 美元。</p>
<ul>
<li>這些股票的收益未達預期，但下個季度將反彈</li>
</ul>
<p><strong>查看我們對 PFE 的最新分析</strong></p>
<h2>內部買入和賣出</h2>
<p>在相關消息中，董事 Ronald E. Blaylock 於 2 月 13 日星期四購買了 19,457 股該公司的股票。每股平均價格為 25.65 美元，總交易額為 499,072.05 美元。購買後，該董事現在直接持有 27,707 股公司股票，價值 710,684.55 美元。此交易代表其持股增加了 235.84%。該購買在向證券交易委員會的文件中披露，相關文件可通過此鏈接獲取。公司內部人士持有 0.06% 的股票。</p>
<h2>關於輝瑞</h2>
<p>（免費報告）</p>
<p>輝瑞公司在美國、歐洲及國際上發現、開發、生產、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在滿足醫療需求的傳染病領域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及潛在的未來 mRNA 和抗病毒產品，品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過輝瑞</li>
<li>紐約證券交易所和納斯達克的區別，以及這對投資者的重要性</li>
<li>抗關税股票：三隻具有巨大上漲潛力的大便宜股</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>高通股價下跌，但相對強弱指數顯示其嚴重超賣</li>
<li>三隻股票引領迷因股復興</li>
<li>特斯拉的頭號看漲者下調目標價，但仍表示值得購買</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

<p>Advisory Services Network LLC 在第四季度將其在輝瑞公司（NYSE:PFE）的持股增加了 3.5%，額外購買了 11,502 股，使其總持股達到 339,805 股，價值 9,015,000 美元。其他機構投資者也增加了在輝瑞的持倉。該股票開盤價為 21.75 美元，市值為 1233.3 億美元。輝瑞報告的季度每股收益為 0.63 美元，超出預期，分析師預計財年的每股收益為 2.95 美元。該股票的共識評級為 “適度買入”，目標價格為 31.07 美元</p>

<p>Advisory Services Network LLC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 339,805 shares of the biopharmaceutical company's stock after purchasing an additional 11,502 shares during the quarter. Advisory Services Network LLC's holdings in Pfizer were worth $9,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Advisory Services Network LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中披露，其在輝瑞公司（NYSE:PFE - 免費報告）的持股在第四季度增加了 3.5%。該基金在季度內購買了額外的 11,502 股後，持有該生物製藥公司 339,805 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Advisory Services Network LLC 在輝瑞的持股價值為 9,015,000 美元。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>關注這兩隻醫療保健股票，因為摩根大通提升了吉利德的評級</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Nordea Investment Management AB lifted its stake in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI raised its holdings in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after purchasing an additional 159,984 shares during the last quarter. Copley Financial Group Inc. bought a new position in Pfizer during the third quarter valued at approximately $577,000. Geode Capital Management LLC grew its position in Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the period. Finally, Mcdonald Partners LLC grew its position in Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares during the period. 68.36% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也調整了對 PFE 的持股。Nordea Investment Management AB 在第四季度將其在輝瑞的股份增加了 36.1%。Nordea Investment Management AB 目前持有 4,071,700 股該生物製藥公司的股票，價值 108,002,000 美元，此前在該期間內又收購了 1,080,822 股。Parsons Capital Management Inc. RI 在第四季度將其在輝瑞的持股增加了 118.7%。Parsons Capital Management Inc. RI 目前持有 294,764 股該生物製藥公司的股票，價值 7,820,000 美元，此前在上個季度又購買了 159,984 股。Copley Financial Group Inc. 在第三季度購買了輝瑞的新頭寸，價值約 577,000 美元。Geode Capital Management LLC 在第三季度將其在輝瑞的持股增加了 1.6%。Geode Capital Management LLC 目前持有 117,666,245 股該生物製藥公司的股票，價值 3,392,342,000 美元，此前在該期間內又購買了 1,855,419 股。最後，Mcdonald Partners LLC 在第四季度將其在輝瑞的持股增加了 9.9%。Mcdonald Partners LLC 目前持有 110,296 股該生物製藥公司的股票，價值 2,926,000 美元，此前在該期間內又購買了 9,963 股。68.36% 的股票由機構投資者持有。</p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>輝瑞價格表現</h2>
</div><p>Shares of Pfizer stock opened at $21.75 on Wednesday. The company has a market capitalization of $123.33 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50-day simple moving average is $25.59 and its 200-day simple moving average is $26.58. Pfizer Inc. has a 52 week low of $21.19 and a 52 week high of $31.54.</p>
<div class="lb-trans"><p>輝瑞股票週三開盤價為 21.75 美元。該公司的市值為 1233.3 億美元，市盈率為 15.42，PEG 比率為 0.64，貝塔值為 0.67。該公司的速動比率為 0.73，流動比率為 1.00，債務股本比率為 0.63。該股票的 50 日簡單移動平均線為 25.59 美元，200 日簡單移動平均線為 26.58 美元。輝瑞公司的 52 周低點為 21.19 美元，52 周高點為 31.54 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm's revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 2 月 4 日星期二發佈了季度財報。這家生物製藥公司報告該季度每股收益為 0.63 美元，超出分析師一致預期的 0.48 美元，超出幅度為 0.15 美元。輝瑞的股本回報率為 19.47%，淨利潤率為 12.62%。該公司該季度的收入為 177.6 億美元，而分析師預期為 172.6 億美元。在去年同期，該公司每股收益為 0.10 美元。與去年同期相比，該公司的收入增長了 24.7%。整體來看，分析師預計輝瑞公司在當前財政年度的每股收益將達到 2.95。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>A number of equities analysts have recently issued reports on PFE shares. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, December 18th. Guggenheim reissued a &#34;buy&#34; rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a &#34;neutral&#34; rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. The Goldman Sachs Group restated a &#34;neutral&#34; rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday. Finally, Hsbc Global Res upgraded shares of Pfizer to a &#34;strong-buy&#34; rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $31.07.</p>
<div class="lb-trans"><p>一些股票分析師最近對 PFE 股票發佈了報告。Truist Financial 將輝瑞的目標價從 36.00 美元下調至 32.00 美元，並在 12 月 18 日的研究報告中對該股票給予了 “買入” 評級。Guggenheim 在 3 月 18 日的研究報告中重申了對輝瑞股票的 “買入” 評級。美國銀行在 12 月 10 日的研究報告中重申了 “中性” 評級，並將輝瑞股票的目標價設定為 29.00 美元。高盛集團在週二的研究報告中重申了 “中性” 評級，並將輝瑞股票的目標價設定為 25.00 美元（從 32.00 美元下調）。最後，滙豐全球研究在 3 月 10 日的研究報告中將輝瑞股票的評級提升至 “強力買入”。一位投資分析師對該股票給予了賣出評級，八位分析師給予了持有評級，六位分析師給予了買入評級，三位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，輝瑞目前的平均評級為 “適度買入”，共識目標價為 31.07 美元。</p>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>這些股票的收益未達預期，但下個季度將反彈</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我們對 PFE 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買入和賣出</h2>
</div><p>In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Ronald E. Blaylock 於 2 月 13 日星期四購買了 19,457 股該公司的股票。每股平均價格為 25.65 美元，總交易額為 499,072.05 美元。購買後，該董事現在直接持有 27,707 股公司股票，價值 710,684.55 美元。此交易代表其持股增加了 235.84%。該購買在向證券交易委員會的文件中披露，相關文件可通過此鏈接獲取。公司內部人士持有 0.06% 的股票。</p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>關於輝瑞</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>輝瑞公司在美國、歐洲及國際上發現、開發、生產、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在滿足醫療需求的傳染病領域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及潛在的未來 mRNA 和抗病毒產品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過輝瑞</li>
<li>紐約證券交易所和納斯達克的區別，以及這對投資者的重要性</li>
<li>抗關税股票：三隻具有巨大上漲潛力的大便宜股</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>高通股價下跌，但相對強弱指數顯示其嚴重超賣</li>
<li>三隻股票引領迷因股復興</li>
<li>特斯拉的頭號看漲者下調目標價，但仍表示值得購買</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Advisory Services Network LLC Acquires 11,502 Shares of Pfizer Inc. (NYSE:PFE)

- Advisory Services Network LLC 在第四季度增持 Pfizer 股份 3.5%。  
- Nordea Investment Management AB 和 Parsons Capital Management Inc. RI 也分別增持 Pfizer 股份。  
- Pfizer 最新季度收益超出預期，收入同比增長 24.7%。  

Advisory Services Network LLC 收購了輝瑞公司（NYSE:PFE）的 11,502 股股票